0:00
11:00
@ michaelsalzle Patients with diabetes and chronic disease are at high risk for kidney failure, cardiovascular events, and death. The FLOW trial looked at the safety and efficacy of semaglutide in patients with chronic disease and type 2 diabetes.
Fler avsnitt från "Healthspan"
Missa inte ett avsnitt av “Healthspan” och prenumerera på det i GetPodcast-appen.